Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

Trial Profile

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary) ; Isoniazid; Pyridoxine; Rifapentine
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Mar 2018 Planned number of patients changed from 30 to 50.
    • 03 Feb 2018 Results (n=4) assessing pharmacokinetic drug-drug interactions between once-weekly isoniazid and rifapentine regimen and dolutegravir, were published in the Clinical Infectious Diseases.
    • 08 Jul 2017 Planned number of patients changed from 60 to 30.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top